The ABPI Wales has today responded to a Welsh Government written statement on the publication of The Independent Review of the Individual Patient Funding Request (IPFR) Process.
Wales Director, Dr Richard Greville, said:
"The Association of the British Pharmaceutical Industry (ABPI) welcomed the opportunity to give evidence to the independent review of the Individual Patient Funding Request (IPFR) process in Wales.
Our members are committed to submitting innovative new treatments to the National Institute for Health and Care Excellence (NICE) and the All Wales Medicines Strategy Group (AWMSG), where the comprehensive evidence needed is available to support this. Where this evidence is not available, it is only fair that a process exists which can enable individual patients, with the support of their clinicians, to be considered for treatments in a fair and transparent way.
We look forward to continuing the mature relationship we have established with Welsh Government to support patients, wherever they live in Wales, to get access to the medicines they may benefit from."
ABPI Press OfficeEmail: firstname.lastname@example.org to 5pm Monday to Friday: +44 (0) 20 7747 7147 or +44 (0) 20 7747 14415pm to 9am and weekends: +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.